The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012
Open accessAbstract
Background: Intrahepatic cholangiocarcinomas (ICCs) and extrahepatic cholangiocarcinomas (ECCs) are highly lethal bile duct tumors. Their incidence can be difficult to estimate because of changes in cancer coding over time. No studies to date have examined their global incidence and trends with high‐quality topography‐ and histology‐specific cancer registry data. Therefore, this study examined ICC and ECC incidence with the Cancer Incidence in Five Continents Plus database. Methods: Regional and national cancer registry data were used to estimate age‐standardized incidence rates (ASRs) per 100,000 person‐years, 95% confidence intervals, and average annual percent changes (AAPCs) for ICC in 38 countries and for ECC in 33 countries from 1993 to 2012. ICC and ECC trends were tabulated and plotted by country. Rates versus birth cohort by age were plotted, and an age‐period‐cohort analysis was performed to assess age and cohort incidence rate ratios. Results: The highest rates of ICC and ECC were in Asia, specifically South Korea (ASR for ICC, 2.80; ASR for ECC, 2.24), Thailand (ASR for ICC, 2.19; ASR for ECC, 0.71), and Japan (ASR for ICC, 0.95; ASR for ECC, 0.83). Between 1993 and 2012, incidence rates of both ICC and ECC increased in most countries. The largest ASR increases over the study period occurred in Latvia (AAPC, 20.1%) and China (AAPC, 11.1%) for ICC and in Thailand (AAPC, 8.8%) and Colombia (AAPC, 8.5%) for ECC. Conclusions: In the 20 years examined, ICC and ECC incidence increased in the majority of countries worldwide. ICC and ECC incidence may continue to increase because of metabolic and infectious etiologic factors. Efforts to further elucidate risk factors contributing to these increases in incidence are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, incidence rates in formerly low-risk countries, most countries across Europe, North America, Australia/New Zealand, and South America have increased or stabilized at a higher level in recent years, 125,128 possibly in part because of increasing prevalence of metabolic risk factors, such as excess body weight, diabetes, nonalcoholic fatty liver disease, and alcohol consumption.”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [128]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Classification of Diseases for Oncology
Trott, P. A. (1977) · Journal of Clinical Pathology · doi:10.1136/jcp.30.8.782-c · Cited by 1,688
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,331
Nakeeb, A., Pitt, H. A., Riall, T. S., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,207
Risk factors for cholangiocarcinoma
Tyson, G. L., & El‐Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 967
Non-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 788
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 787
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El‐Serag, H. B., Vecchia, C. L., & Negri, E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.013 · Cited by 661
Bray, F., & Parkin, D. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.032 · Cited by 634
Self-citationRisk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study
Shaib, Y. H., El‐Serag, H. B., Davila, J. A., Morgan, R. O., & McGlynn, K. A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.048 · Cited by 545
Self-citationEvaluation of data quality in the cancer registry: Principles and methods Part II. Completeness
Parkin, D. M., & Bray, F. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.033 · Cited by 536
Self-citation
Research works printed but not linked: 3
- Fritz A, 2000, International Classification of Diseases for Oncology (ICD‐O)
- Ferlay J, 2018, Cancer Incidence in Five Continents, CI5plus: IARC CancerBase No. 9
- World Health Organization, 1985, International Classification for Diseases
Cited by
Sorted by citations
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Self-citationBray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
“…countries across Europe, North America, Australia/New Zealand, and South America have increased or stabilized at a higher level in recent years, 125,128 possibly in part because of increasing prevalence of metabolic risk factors, such as excess body weight, diabetes, nonalcoholic fatty liver…”
BackgroundSelf-citationGlobal burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197
Self-citationGlobal, regional and national burden of primary liver cancer by subtype
Rumgay, H., Ferlay, J., de Martel, C., Georges, D., Ibrahim, A. S., Zheng, R., Wei, W., Lemmens, V. E. P. P., & Soerjomataram, I. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.023 · Cited by 615
Self-citationMoris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 457
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
Targeting FGFR inhibition in cholangiocarcinoma
Goyal, L., Kongpetch, S., Crolley, V. E., & Bridgewater, J. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102170 · Cited by 185
Bekaii-Saab, T. S., Valle, J. W., Cutsem, E. V., Rimassa, L., Furuse, J., Ioka, T., Melisi, D., Macarulla, T. M., Bridgewater, J. A., Wasan, H. S., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0429 · Cited by 178
Practical considerations in screening for genetic alterations in cholangiocarcinoma
Bekaii‐Saab, T., Bridgewater, J. A., & Normanno, N. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.012 · Cited by 137
Javle, M. M., Lee, S., Azad, N. S., Borad, M. J., Kelley, R. K., Sivaraman, S., Teschemaker, A. R., Chopra, I., Janjan, N. A., Parasuraman, S. V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac150 · Cited by 95
Chung, T., & Park, Y. N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.857140 · Cited by 87
Ruffolo, L. I., Jackson, K. M., Kuhlers, P. C., Dale, B. S., Figueroa-Guilliani, N., Ullman, N. A., Burchard, P. R., Qin, S., Juviler, P. G., Keilson, J. M., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324109 · Cited by 79
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Krenzien, F., Nevermann, N., Krombholz, A., Benzing, C., Haber, P., Fehrenbach, U., Lurje, G., Pelzer, U., Pratschke, J., Schmelzle, M., et al. (2022) · Cancers · doi:10.3390/cancers14020362 · Cited by 78
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma
Carapeto, F. C. L., Bozorgui, B., Shroff, R. T., Chagani, S., Soto, L. M. S., Foo, W. C., Wistuba, I. I., Meric‐Bernstam, F., Shalaby, A., Javle, M. M., et al. (2021) · Hepatology · doi:10.1002/hep.32150 · Cited by 68
Najafi, M., Mortezaee, K., Rahimifard, M., Farhood, B., & Haghi‐Aminjan, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118051 · Cited by 65
Diagnosis of Cholangiocarcinoma
Shin, D. W., Moon, S., & Kim, J. H. (2023) · Diagnostics · doi:10.3390/diagnostics13020233 · Cited by 59
Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma
Vilà, P. C., Ravichandra, A., Lizaso, A. A., Perugorria, M. J., & Affò, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000206 · Cited by 62
Systemic treatment of advanced or recurrent biliary tract cancer
Zhang, W., Zhou, H., Wang, Y., Zhang, Z., Cao, G., Song, T., Zhang, T., & Li, Q. (2020) · BioScience Trends · doi:10.5582/bst.2020.03240 · Cited by 56
Chemotherapy for Biliary Tract Cancer in 2021
Sasaki, T., Takeda, T., Okamoto, T., Ozaka, M., & Sasahira, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143108 · Cited by 43
Role of molecular genetics in the clinical management of cholangiocarcinoma
Normanno, N., Martinelli, E., Melisi, D., Pinto, C., Rimassa, L., Santini, D., & Scarpa, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100505 · Cited by 45
Chen, Y., Xu, X., Wang, Y., Zhang, Y., Zhou, T., Jiang, W., Wang, Z., Chang, J., Liu, S., Chen, R., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02842-7 · Cited by 44
Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Woods, E., Le, D. T., Jakka, B. K., & Manne, A. (2022) · Cancers · doi:10.3390/cancers14092137 · Cited by 44
Kang, M. J., Lim, J., Han, S., Park, H. M., Kim, S., Lee, W. J., Woo, S. M., Kim, T. H., Won, Y., & Park, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13605-3 · Cited by 43
An, L., Zheng, R., Zhang, S., Chen, R., Wang, S., Sun, K., Lu, L., Zhang, X., Zhao, H., Zeng, H., et al. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-75 · Cited by 41
Surgical management of intrahepatic cholangiocarcinoma
Hewitt, D. B., Brown, Z. J., & Pawlik, T. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.1999809 · Cited by 41
Immunotherapy in Advanced Biliary Tract Cancers
Boilève, A., Hilmi, M., Smolenschi, C., Ducreux, M. P., Hollebecque, A., & Malka, D. (2021) · Cancers · doi:10.3390/cancers13071569 · Cited by 41
Huang, W., Liao, Z., Zhang, J., Zhang, X., Zhang, H., Liang, H., Zhang, Z., Yang, T., Yu, J., & Dong, K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05363-x · Cited by 41
Macarulla, T. M., Ren, Z., Chon, H. J., Park, J. O., Kim, J. W., Pressiani, T., Li, D., Zhukova, L., Zhu, A. X., Chen, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00337 · Cited by 39
Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland
Barner‐Rasmussen, N., Pukkala, ., Hadkhale, K., & Färkkilä, M. A. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12154 · Cited by 38
Jackson, S. S., Adami, H., Andreotti, G., Freeman, L. E. B., de González, A. B., Buring, J. E., Fraser, G. E., Freedman, N. D., Gapstur, S. M., Gierach, G. L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.046 · Cited by 39
Self-citationSaengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 40
Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine
Gopal, P., Robert, M. E., & Zhang, X. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0537-ra · Cited by 37
Liu, Z., Hu, C., Zheng, L., Liu, J., Li, K., Li, X., Wang, Y., Mu, W., Chen, T., Shi, A., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04500-1 · Cited by 37
Xu, X. L., Chen, Y., Shao, S., Wang, J., Shan, J., Wang, Y., Wang, Y., Chang, J., Zhou, T., Chen, R., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90774 · Cited by 33
Xiao, P., Meng, Q., Liu, Q., Lang, Q., Yin, Z., Li, G., Li, Z., Xu, Y., Yu, Z., Geng, Q., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216075 · Cited by 33
Capuozzo, M., Santorsola, M., Ferrara, F., Cinque, C., Farace, S., Patrone, R., Granata, V., Zovi, A., Nasti, G., & Ottaiano, A. (2024) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2024.101951 · Cited by 31
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
King, G. T., & Javle, M. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01100-3 · Cited by 30
Bibeau, K. B., Féliz, L. R., Lihou, C. F., Ren, H., & Abou‐Alfa, G. K. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00414 · Cited by 30
Zhu, J., Liu, C., Li, H., Ren, H., Cai, Y., Lan, T., & Wu, H. M. (2023) · Cancer Medicine · doi:10.1002/cam4.5620 · Cited by 29
Unresectable biliary tract cancer: Current and future systemic therapy
Zhang, D., Dorman, K., Westphalen, C. B., Haas, M., Ormanns, S., Neumann, J. H. L., Seidensticker, M., Ricke, J., Toni, E. N. D., Klauschen, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114046 · Cited by 28
Kongkam, P., Khoo, S., & Tri, N. (2020) · Endoscopic Ultrasound · doi:10.4103/eus.eus_59_20 · Cited by 28
Epidemiology of cholangiocarcinoma
Turati, F., Bertuccio, P., Negri, E., & Vecchia, C. L. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.130 · Cited by 29
Saengboonmee, C., Phoomak, C., Supabphol, S., Covington, K. R., Hampton, O. A., Wongkham, C., Gibbs, R. A., Umezawa, K., Seubwai, W., Gingras, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118548 · Cited by 27
Høgdall, D., O’Rourke, C. J., Larsen, F. O., Zarforoushan, S., Christensen, T. D., Ghazal, A., Boisen, M. K., Muñoz-Garrido, P., Johansen, J. S., & Andersen, J. B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.036 · Cited by 29
Chao, J., Wang, S., Wang, H., Zhang, N., Wang, Y., Yang, X., Zhu, C., Ning, C., Zhang, X., Xue, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03523-2 · Cited by 26
Oliviero, B., Varchetta, S., Mele, D., Pessino, G., Maiello, R., Falleni, M., Tosi, D., Donadon, M., Soldani, C., Franceschini, B., et al. (2022) · Oncoimmunology · doi:10.1080/2162402x.2022.2035919 · Cited by 31
Liu, N., Wu, Y.-K., Tao, Y.-Y., Zheng, J., Huang, X., Yang, L., & Zhang, X. M. (2023) · Cancers · doi:10.3390/cancers15225373 · Cited by 26
Adverse events of sorafenib in hepatocellular carcinoma treatment.
Pang, Y., Eresen, A., Zhang, Z., Hou, Q., Wang, Y., Yaghmai, V., & Zhang, Z. (2022) · PubMed Central · Cited by 25
Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., Pazienza, V., Guerrera, L. P., Amoruso, B., Normanno, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020820 · Cited by 23
Shi, G., Huang, X., Wen, T., Song, T.-Q., Kuang, M., Mou, H., Bao, L., Zhao, H., Zhao, H., Feng, X., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5273 · Cited by 22
An overview of extrahepatic cholangiocarcinoma: from here to where?
Yang, Y., & Zhang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171098 · Cited by 22
Kolck, J., Auer, T. A., Walter, T., Hosse, C., Elkilany, A., Marth, A. A., Pelzer, U., Mohr, R. U., Krenzien, F., Lurje, G., et al. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03991-1 · Cited by 22
Zhang, X., Cai, Y., Xiong, X., Liu, A., Zhou, R., You, Z., Li, F., & Cheng, N. (2022) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2022.01109 · Cited by 21
Ayabe, R. I., Paez-Arango, N., Estrella, J. S., Newhook, T. E., Tzeng, C.-W. D., Chun, Y. S., Lee, S., Javle, M. M., Vauthey, J., & Cao, H. S. T. (2023) · HPB · doi:10.1016/j.hpb.2023.01.011 · Cited by 20
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations
Wilbur, H. C., Soares, H. P., & Azad, N. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000760 · Cited by 21
Vijay, V., Karisani, N., Shi, L., Hung, Y.-H., Vu, P., Kattel, P., Kenney, L., Merritt, J., Adil, R., Wu, Q., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1383 · Cited by 21
Characteristics and clinical outcomes in young‐onset cholangiocarcinoma
Reddy, S., Goksu, S. Y., Sanford, N. N., Kainthla, R., Hsiehchen, D., Sanjeevaiah, A. R., Jones, A. L., Karagkounis, G., Mutar, S. S. A., Ahn, C. W., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6063 · Cited by 20
Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations
Osataphan, S. A., Mahankasuwan, T., & Saengboonmee, C. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1001 · Cited by 20
Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study
Chen, X., Rong, D., Zhang, L., Ni, C., Han, G., Lu, Y., Chen, X., Gao, Y., & Wang, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2785 · Cited by 20
Zugman, M., Botrus, G., Pestana, R. C., & Usón, P. L. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860453 · Cited by 19
Wu, G., Wang, Q., Wang, D., Xiong, F., Liu, W., Chen, J., Wang, B., Huang, W., Wang, X., & Chen, Y. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1502 · Cited by 18
Bile is a reliable and valuable source to study cfDNA in biliary tract cancers
Li, Z., Liu, Y., Fu, J., Mugaanyi, J., Yan, J., Lu, C., & Huang, J. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961939 · Cited by 17
Peng, J., Fang, S., Li, M., Liu, Y., Liang, X., Li, Z., Chen, G., Peng, L., Chen, N., Liu, L., et al. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0652 · Cited by 17
Liu, W., Ji, H., Zhao, J., Song, J., Zheng, S., Chen, L., Li, P., Tan, X., Ding, Y., Pu, R., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33930 · Cited by 17
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives
Geyik, Ö. G., Anichini, G., Ulukaya, E., Marra, F., & Raggi, C. (2022) · Cells · doi:10.3390/cells11091463 · Cited by 18
Toshida, K., Itoh, S., Harada, N., Morinaga, A., Yugawa, K., Tomiyama, T., Kosai‐Fujimoto, Y., Tomino, T., Kurihara, T., Nagao, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15644 · Cited by 15
Wang, X., Fu, X., Qian, Z., Zhao, T., Duan, A., Ruan, X., Zhu, B., Yin, L., Zhang, Y., & Yu, W. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100908 · Cited by 16
A New Prognostic Model Covering All Stages of Intrahepatic Cholangiocarcinoma
Zhou, S.-N., Lu, S.-S., Da-wei, J., Yu, L., Liang, X., Xiang, X., Liangpunsakul, S., Roberts, L. R., Lu, Y., & Zhang, N. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00099 · Cited by 16
Prognostic Impact of Paraaortic Lymph Node Metastasis in Extrahepatic Cholangiocarcinoma
Nitta, N., Ohgi, K., Sugiura, T., Okamura, Y., Ito, T., Yamamoto, Y., Ashida, R., Otsuka, S., Sasaki, K., & Uesaka, K. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05834-2 · Cited by 15
Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy
Brown, Z. J., Hewitt, D. B., & Pawlik, T. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703085 · Cited by 15
Prognostic impact of tumor vascularity on CT in resectable intrahepatic cholangiocarcinoma
Park, H. M., Jang, H. Y., Lee, D. E., Kang, M. J., Han, S., Kim, S., & Park, S. (2021) · HPB · doi:10.1016/j.hpb.2021.06.424 · Cited by 14
Miao, X., Hu, J., Chai, C., Tang, H., Zhao, Z., Luo, W., Zhou, W., & Xu, H. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02840-3 · Cited by 15
Auer, T. A., Collettini, F., Segger, L., Pelzer, U., Mohr, R. U., Krenzien, F., Gebauer, B., Geisel, D., Hosse, C., Schöning, W., et al. (2023) · Cancers · doi:10.3390/cancers15092655 · Cited by 14
Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes
Chen, Z., Gao, J., Li, Z., Ma, D., Wang, Y., Cheng, Q., Zhu, J., & Zhao, L. (2024) · Liver International · doi:10.1111/liv.16015 · Cited by 15
Neuzillet, C., Artru, P., Assénat, E., Edeline, J., Adhoute, X., Sabourin, J., Turpin, A., Coriat, R., & Malka, D. (2023) · Targeted Oncology · doi:10.1007/s11523-022-00942-6 · Cited by 14
Tsilimigras, D. I., Han, X., Guglielmi, A., Aldrighetti, L. A., Weiss, M. J., Bauer, T. W., Alexandrescu, S. T., Poultsides, G. A., Maithel, S. K., Marques, H. P., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15013-5 · Cited by 13
Kratz, J. D., Klein, A. B., Gray, C. B., Märten, A., Vilu, H.-L., Knight, J. F., Kumichel, A., & Ueno, M. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01086-5 · Cited by 12
Jiang, H., Gao, B., Meng, Z., Wang, Y., Jiao, T., Li, J., Li, X. H., Cao, Y., Zhang, X., Li, C., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05750-2 · Cited by 13
Silverman, I. M., Li, M., Murugesan, K., Krook, M. A., Javle, M. M., Kelley, R. K., Borad, M. J., Roychowdhury, S., Meng, W., Yilmazel, B., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.12.012 · Cited by 13
Dotto-Vasquez, G., Villacorta-Ampuero, A. K., Ulloque‐Badaracco, J. R., Hernández-Bustamante, E. A., Alarcón‐Braga, E. A., Herrera‐Añazco, P., Benites-Zapata, V. A., & Hernández, A. V. (2022) · Diagnostics · doi:10.3390/diagnostics12112655 · Cited by 13
Surgical Aspects of Intrahepatic Cholangiocarcinoma
Kupietzky, A., & Ariche, A. (2022) · Cancers · doi:10.3390/cancers14246265 · Cited by 13
Toshida, K., Itoh, S., Iseda, N., Izumi, T., Yoshiya, S., Toshima, T., Ninomiya, M., Iwasaki, T., Oda, Y., & Yoshizumi, T. (2023) · Cancer Science · doi:10.1111/cas.15981 · Cited by 13
Paraneoplastic syndromes in cholangiocarcinoma
Rahman, S. U., Sana, M. K., Tahir, Z., Ali, A., & Shah, P. A. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i11.897 · Cited by 13
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma
Hoffmeister‐Wittmann, P., Möck, A., Nichetti, F., Korell, F., Heilig, C. E., Scherr, A., Günther, M., Albrecht, T., Kelmendi, E., Xu, K., et al. (2022) · Liver International · doi:10.1111/liv.15392 · Cited by 12
Spatial and temporal analysis of liver cancer mortality in Yunnan province, China, 2015–2019
Feng, C., Liu, J., Ran, H., Wu, L., Liang, X., Sun, H., Xiao, Y., & Chang, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1010752 · Cited by 12
Anchalee, N., Thinkhamrop, K., Suwannatrai, A. T., Titapun, A., Loilome, W., & Kelly, M. J. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.2.537 · Cited by 12
Yoshizawa, T., Uehara, T., Iwaya, M., Nakajima, T., Shimizu, A., Kubota, K., Notake, T., Kitagawa, N., Masuo, H., Sakai, H., et al. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002224 · Cited by 12
Vu, Q. T., Nishimura, Y., Harada, K., Ito, H., Higashionna, T., Maruo, A., Harada, K., Takeda, T., Hamano, H., Zamami, Y., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001200 · Cited by 12
Thinkhamrop, K., Khuntikeo, N., Chamadol, N., Suwannatrai, A. T., Phimha, S., & Kelly, M. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-17794-9 · Cited by 12
Prinz, C., Frese, R., Grams, M., & Fehring, L. (2022) · Genes · doi:10.3390/genes13081479 · Cited by 12
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
Garajová, I., Gelsomino, F., Salati, M., Leonardi, F., Lorenzo, S. D., Granito, A., & Tovoli, F. (2023) · Current Oncology · doi:10.3390/curroncol30030199 · Cited by 12
Kang, M. J., Lim, J., Han, S., Park, H. M., Kim, S., Won, Y., & Park, S. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.916 · Cited by 12
Jung, K., Park, J., Jung, J. H., Lee, J.-C., Kim, J., & Hwang, J. (2022) · Gut and Liver · doi:10.5009/gnl210346 · Cited by 11
Qin, S., Pan, G., Meng, Q.-B., Liu, J., Tian, Z., & Luan, S.-J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203685 · Cited by 11
Current Advances in Basic and Translational Research of Cholangiocarcinoma
Sato, K., Baiocchi, L., Kennedy, L. L., Zhang, W., Ekser, B., Glaser, S. S., Francis, H., & Alpini, G. D. (2021) · Cancers · doi:10.3390/cancers13133307 · Cited by 10
Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma
Wu, Y., Khizar, H., Hu, Y., & Yang, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.890605 · Cited by 11
Clonorchis sinensis infection modulates key cytokines for essential immune response impacted by sex
Kan, S., Li, Q., Li, H., Yao, Y., Du, X.-Y., Wu, C.-Y., Chen, G., Guo, X., Qian, M., & Wang, Z. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010726 · Cited by 10
Clinical characteristics and prognosis of early-onset cholangiocarcinoma: a population-based study
Gao, F., Xu, X., & Sun, Y. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2277663 · Cited by 10
Jiang, N., Zhang, Z., Yin, X., Qiu, H., Yan, W., Hao, Y., Yang, W., Li, H., Xu, A., & Mu, K. (2024) · La radiologia medica · doi:10.1007/s11547-024-01781-3 · Cited by 10
The clinical value of regional lymphadenectomy for intrahepatic cholangiocarcinoma
Yang, F., Wu, C., Bo, Z., Xu, J., Yi, B., Li, J., & Qiu, Y. (2021) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2021.06.031 · Cited by 10
Metadata
- Authors
- Florio, A. A., Ferlay, J., Znaor, A., Ruggieri, D., Alvarez, C. S., Laversanne, M., Bray, F., McGlynn, K. A., & Petrick, J. L.
- Affiliations
- National Cancer Institute (US)
- Centre international de recherche sur le cancer (FR)
- Information Management Services (US)
- Division of Cancer Epidemiology and Genetics National Cancer Institute Bethesda Maryland
- Boston University (US)
- Corresponding author
- Petrick, Jessica L.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-03-04
- Volume
- 126
- Issue
- 11
- Pages
- 2666-2678
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC7323858
- OpenAlex
- W3009424821
- Cited by
- 304
- References
- 46
- Citations by year
- 2026: 31 · 2025: 51 · 2024: 66 · 2023: 49 · 2022: 55 · 2021: 37 · 2020: 14
- FWCI
- 35.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, cholangiocarcinoma, cancer incidence trends, age-standardized incidence rate, global cancer incidence, age-period-cohort analysis, birth cohort effects, risk factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms, Female, Humans, Male, Middle Aged, Time Factors, Incidence, Cholangiocarcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
